MarketCap
Facebook
X
TelegramAnnual report 2025
added 01-17-2026
China SXT Pharmaceuticals Total Shareholders Equity 2011-2026 | SXTC
Annual Total Shareholders Equity China SXT Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.4 M | 13.9 M | 14.7 M | 16.1 M | 16 M | 9.4 M | 11.1 M | 3.29 M | 1.85 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.1 M | 1.85 M | 11.3 M |
Quarterly Total Shareholders Equity China SXT Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 16.4 M | - | 13.8 M | - | 16 M | - | 18.5 M | - | 9.4 M | - | 11.4 M | - | 11.1 M | - | 4.6 M | - | 3.29 M | - | - | - | 1.85 M | - | - | - | 743 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 18.5 M | 743 K | 9.74 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
50.5 M | $ 2.62 | 28.82 % | $ 147 M |  China |
 |
GlaxoSmithKline plc
GSK
|
20.8 B | $ 48.98 | 0.68 % | $ 173 B |  Britain |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.51 | 7.34 % | $ 8.45 B |  Australia |
 |
Grifols, S.A.
GRFS
|
6.72 B | $ 9.25 | 1.49 % | $ 6.83 B |  Spain |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Galapagos NV
GLPG
|
2.67 B | $ 34.61 | 0.61 % | $ 2.69 B |  Belgium |
 |
BioLineRx Ltd.
BLRX
|
22 M | $ 3.1 | 4.49 % | $ 908 M |  Israel |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Zoetis
ZTS
|
4.77 B | $ 123.99 | -0.31 % | $ 56.3 B | USA |
 |
BioNTech SE
BNTX
|
1.37 B | $ 116.27 | -1.86 % | $ 27.2 B | Germany |
 |
Ascendis Pharma A/S
ASND
|
884 M | $ 235.41 | 2.95 % | $ 5 B |  Danmark |
 |
Burford Capital Limited
BUR
|
1.7 B | $ 9.74 | -1.37 % | $ 1.55 B | Britain |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
466 M | $ 67.49 | -3.02 % | $ 9.03 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.44 M | $ 4.51 | 8.41 % | $ 9.81 B | Israel |
 |
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
518 M | - | - | $ 1.01 B | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
39.5 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
732 M | $ 25.92 | -0.86 % | $ 1.26 B | USA |
 |
Amneal Pharmaceuticals
AMRX
|
-109 M | $ 13.49 | -0.66 % | $ 4.17 B | USA |
 |
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Aptose Biosciences
APTO
|
-4.54 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | USA |
 |
Athira Pharma
ATHA
|
44.8 M | - | - | $ 269 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
AVROBIO
AVRO
|
94.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
19 M | $ 2.66 | -1.85 % | $ 16.7 M | USA |
 |
AstraZeneca PLC
AZN
|
15.6 B | $ 92.87 | 1.28 % | $ 96.9 B | Britain |
 |
Arena Pharmaceuticals
ARNA
|
673 M | - | -6.81 % | $ 3.04 B | USA |
 |
Brickell Biotech
BBI
|
9.93 M | - | -5.38 % | $ 6.06 M | USA |
 |
Athersys
ATHX
|
16.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.33 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
16.7 B | $ 171.89 | -1.1 % | $ 25 B | USA |